S&P 500 7,721.63 ▲ 44.86 (+0.58%) DOW 52,371.80 ▲ 10.22 (+0.02%) NASDAQ 26,483.24 ▲ 313.86 (+1.20%) US Markets Open â€ĸ 12:41 PM ET

JBIO

Jade Biosciences, Inc.

Price Chart
Latest Quote

$14.86

+0.36 (+2.48%)
Current Price
Previous Close $14.50
Open $14.52
Day High $15.06
Day Low $14.36
Volume 168,523
Fetched: 2026-10-27T16:41:56
Stock Information
Shares Outstanding 63.60M
Total Debt $1.39M
Cash Equivalents $461.20M
Net Income $-124.44M
Sector Healthcare
Industry Biotechnology
Market Cap $945.06M
EPS (TTM) $-1.92
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$462.35M
Income$-124.44M
Book/sh$6.92
Cash/sh$7.25
Employees55
Financial Ratios
Quick Ratio14.61
Current Ratio14.93
Debt/Eq0.32
Returns & Margins
Ownership
Insider Ownership0.79%
Institutional Ownership116.16%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-5.58
P/B2.15
Analyst Data
Recommendationstrong_buy
Target Price$50.12
Technical Indicators
SMA20$14.12
SMA50$16.98
SMA200$18.24
RSI61.19
ATR0.8145
Shares Float51.97M
Short Float23.32%
Short Ratio12.01
Rel Volume0.19
Performance History
Week+0.00%
Month+3.55%
Quarter-23.20%
6 Months-43.82%
YTD+4.94%
Year+48.60%
3 Years-96.09%
5 Years-96.95%
10 Years-98.09%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-10-27 $14.86 168,523
2026-10-26 $14.50 477,500
2026-10-23 $14.59 634,400
2026-10-22 $14.91 575,900
2026-10-21 $15.13 932,700
2026-10-20 $14.86 881,300
2026-10-19 $13.83 828,500
2026-10-16 $13.47 981,000
2026-10-15 $13.76 1,038,900
2026-10-14 $13.44 1,172,700
2026-10-13 $13.42 1,329,200
2026-10-12 $14.00 1,355,600
2026-10-09 $14.39 735,600
2026-10-08 $14.15 1,667,200
2026-10-07 $13.77 951,300
2026-10-06 $13.41 493,900
2026-10-05 $14.07 607,100
2026-10-02 $14.12 1,109,800
2026-10-01 $13.77 1,071,700
2026-09-30 $14.05 930,900
2026-09-29 $14.18 627,500
2026-09-28 $14.35 598,600
About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

📰 Latest News
No news articles available at the moment. Check back later for updates on JBIO.
Period:
Income Statement (Annual)
Metric 2025-12-31
Revenue
Total Revenue $0
Operating Revenue $0
Expenses
Total Expenses $113,542,000
Other Income Expense $-21,592,000
Other Non Operating Income Expenses $-21,592,000
Net Non Operating Interest Income Expense $7,782,000
Operating Expense $113,542,000
General And Administrative Expense $20,421,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-127,410,000
Net Interest Income $7,782,000
Interest Income $7,782,000
Normalized Income $-127,410,000
Net Income From Continuing And Discontinued Operation $-127,410,000
Total Operating Income As Reported $-113,542,000
Net Income Common Stockholders $-127,410,000
Net Income $-127,410,000
Net Income Including Noncontrolling Interests $-127,410,000
Net Income Continuous Operations $-127,410,000
Pretax Income $-127,352,000
Interest Income Non Operating $7,782,000
Operating Income $-113,542,000
Per Share
Diluted EPS $-3.19
Basic EPS $-3.19
Other
Tax Effect Of Unusual Items $0
Tax Rate For Calcs $0
Normalized EBITDA (Bullshit earnings) $-113,516,000
Reconciled Depreciation $26,000
EBITDA (Bullshit earnings) $-113,516,000
EBIT $-113,542,000
Diluted Average Shares $31,359,958
Basic Average Shares $31,359,958
Diluted NI Availto Com Stockholders $-127,410,000
Tax Provision $58,000
Research And Development $93,121,000
Selling General And Administration $20,421,000
Other Gand A $7,730,000
Salaries And Wages $12,691,000
Fetched: 2026-10-20
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31
Assets
Net Tangible Assets $332,518,000 $-46,799,000
Total Assets $349,781,000 $72,799,000
Total Non Current Assets $965,000 $3,145,000
Other Non Current Assets $69,000 $3,145,000
Current Assets $348,816,000 $69,654,000
Other Current Assets $12,658,000 $268,000
Cash Cash Equivalents And Short Term Investments $336,158,000 $69,386,000
Cash And Cash Equivalents $88,438,000 $69,386,000
Debt
Total Debt $724,000 $107,600,000
Long Term Debt And Capital Lease Obligation $724,000 $107,600,000
Net Debt - $38,214,000
Long Term Debt - $107,600,000
Liabilities
Total Liabilities Net Minority Interest $17,263,000 $119,598,000
Total Non Current Liabilities Net Minority Interest $724,000 $107,602,000
Current Liabilities $16,539,000 $11,996,000
Payables And Accrued Expenses $13,216,000 $8,128,000
Payables $2,151,000 $1,290,000
Accounts Payable $2,151,000 $1,290,000
Other Current Liabilities - $1,077,000
Equity
Common Stock Equity $332,516,000 $-46,799,000
Preferred Stock Equity $2,000 -
Total Equity Gross Minority Interest $332,518,000 $-46,799,000
Stockholders Equity $332,518,000 $-46,799,000
Gains Losses Not Affecting Retained Earnings $129,000 $0
Other Equity Adjustments $129,000 -
Retained Earnings $-174,389,000 $-46,979,000
Preferred Securities Outside Stock Equity $0 $2,000
Other
Ordinary Shares Number $49,316,287 $32,235,926
Share Issued $49,316,287 $32,235,926
Tangible Book Value $332,516,000 $-46,799,000
Invested Capital $332,516,000 $60,801,000
Working Capital $332,277,000 $57,658,000
Capital Lease Obligations $724,000 $0
Total Capitalization $332,518,000 $60,801,000
Additional Paid In Capital $506,771,000 $179,000
Capital Stock $7,000 $1,000
Common Stock $5,000 $1,000
Preferred Stock $2,000 $0
Long Term Capital Lease Obligation $724,000 $0
Pensionand Other Post Retirement Benefit Plans Current $3,323,000 $2,791,000
Current Accrued Expenses $11,065,000 $6,838,000
Net PPE $896,000 $0
Gross PPE $896,000 $0
Other Properties $896,000 -
Other Short Term Investments $247,720,000 $0
Fetched: 2026-10-20
Cash Flow Statement (Annual)
Metric 2025-12-31
Free Cash Flow
Free Cash Flow $-94,885,000
Operating Activities
Operating Cash Flow $-94,689,000
Cash Flow From Continuing Operating Activities $-94,689,000
Investing Activities
Capital Expenditure $-196,000
Investing Cash Flow $-247,006,000
Cash Flow From Continuing Investing Activities $-247,006,000
Net Other Investing Changes $-31,000
Financing Activities
Issuance Of Capital Stock $189,111,000
Financing Cash Flow $360,768,000
Cash Flow From Continuing Financing Activities $360,768,000
Net Other Financing Charges $171,273,000
Net Common Stock Issuance $189,111,000
Common Stock Issuance $189,111,000
Other
Issuance Of Debt $0
End Cash Position $88,438,000
Beginning Cash Position $69,386,000
Effect Of Exchange Rate Changes $-21,000
Changes In Cash $19,073,000
Proceeds From Stock Option Exercised $384,000
Net Issuance Payments Of Debt $0
Net Long Term Debt Issuance $0
Long Term Debt Issuance $0
Net Investment Purchase And Sale $-246,779,000
Sale Of Investment $14,415,000
Purchase Of Investment $-261,194,000
Net PPE Purchase And Sale $-196,000
Purchase Of PPE $-196,000
Change In Working Capital $-8,197,000
Change In Other Current Liabilities $40,000
Change In Other Current Assets $-38,000
Change In Payables And Accrued Expense $3,770,000
Change In Accrued Expense $3,409,000
Change In Payable $361,000
Change In Account Payable $361,000
Change In Prepaid Assets $-11,969,000
Other Non Cash Items $21,667,000
Stock Based Compensation $20,009,000
Amortization Of Securities $-784,000
Depreciation Amortization Depletion $26,000
Depreciation And Amortization $26,000
Depreciation $26,000
Net Income From Continuing Operations $-127,410,000
Fetched: 2026-10-20